AGIOS (AGIO) director Catherine Owen Adams converts 1,976 RSUs into common stock

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS director Catherine Owen Adams exercised restricted stock units into common stock. She converted 1,976 restricted stock units into 1,976 shares of common stock at a stated price of $0.00 per share and did not sell any shares. Following the transaction, she directly holds 8,049 shares of common stock. The restricted stock units were granted on June 13, 2023 and vest in three equal annual installments beginning on June 13, 2024, with vested shares delivered within three business days after vesting.

Insider Trade Summary

1,976 shares exercised/converted

Mixed 2 txns

Insider Owen Adams Catherine

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted stock units	1,976	$0.00	--
Exercise	Common stock	1,976	$0.00	--

Holdings After Transaction: Restricted stock units — 0 shares (Direct, null); Common stock — 8,049 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Key Figures

RSUs exercised: 1,976 units Shares received: 1,976 shares Post-transaction holdings: 8,049 shares +2 more

5 metrics

RSUs exercised 1,976 units Restricted stock units converted to common stock on June 13, 2026

Shares received 1,976 shares Common stock issued from RSU conversion at $0.00 per share

Post-transaction holdings 8,049 shares Total AGIOS common stock directly held after the transaction

RSU grant date June 13, 2023 Grant date of the restricted stock units that were exercised

Vesting schedule 3 equal annual installments Beginning June 13, 2024, with delivery within three business days

Key Terms

restricted stock units, derivative security, vest

3 terms

restricted stock units financial

"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vest financial

"Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Owen Adams Catherine

(Last) (First) (Middle)

C/O AGIOS PHARMACEUTICALS, INC.

88 SIDNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	06/13/2026		M		1,976	A	$0	8,049	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted stock units	(1)	06/13/2026		M			1,976	(2)	(2)	Common stock	1,976	$0	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Remarks:

	/s/ William Cook, as attorney-in-fact for Catherine Owen	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did AGIOS (AGIO) report for Catherine Owen Adams?

AGIOS reported that director Catherine Owen Adams exercised 1,976 restricted stock units into 1,976 shares of common stock at a stated price of $0.00 per share, with no shares sold in this filing.

How many AGIOS (AGIO) shares does Catherine Owen Adams hold after this Form 4?

After the reported transactions, Catherine Owen Adams directly holds 8,049 shares of AGIOS common stock. This reflects the addition of 1,976 shares received from the exercise of restricted stock units, with no dispositions reported.

What happened to the restricted stock units in the AGIOS (AGIO) Form 4?

The Form 4 shows 1,976 restricted stock units converted into 1,976 shares of AGIOS common stock. After this conversion, the reported balance of these restricted stock units is 0, indicating this specific RSU position was fully settled into shares.

When were Catherine Owen Adams’ AGIOS (AGIO) restricted stock units granted and how do they vest?

The restricted stock units were granted on June 13, 2023 and begin vesting on June 13, 2024. The shares underlying the units vest in three equal annual installments, with vested shares delivered within three business days after each vesting date.

Did the AGIOS (AGIO) Form 4 disclose any stock sales by Catherine Owen Adams?

The Form 4 does not report any stock sales by Catherine Owen Adams. It records the exercise and conversion of 1,976 restricted stock units into common shares, with no dispositions or open-market sales included in the reported transactions.